Reversine, CAS NO.656820-32-5

reversine, a small synthetic purine analogue (2,6-disubstituted purine), is a potent inhibitior of aurora a/b/c with ic50s of 150-500 nm.
ic50 value: 150 nm (aurora kinase a); 500 nm (aurora kinase b); 400 nm (aurora kinase c) [1]
target: pan-aurora kinase
in vitro: reversine induced apoptosis in pdtc cells with caspase-3 and caspase-8 activation, but not caspase-9. use of a pan-caspase inhibitor before treatment with reversine attenuated cell death [2]. reversine significantly suppressed the proliferation of two oscc cell lines (oc2 and ocsl) and markedly rendered cell cycle arrest at g2/m stage. reversine also induced cell death via both caspase-dependent and -independent apoptosis. in addition,reversine could inhibit akt/mtorc1 signaling pathway, accounting for its ability to induce autophagy [3]. reversine pre-treatment, at very low concentration (50 nm), caused a marked increase in the differentiation yields of both bmscs and ascs [4].
in vivo: in the therapeutic mouse model, tumor weight and tumor volume of cervical cancer bearing mice was more reduced when compared with the control agents (p < 0.05) in tumor-bearing mice [5].